Impact of the COVID-19 Pandemic on Management of Children and Adolescents with Type 1 Diabetes

Abha Choudhary (✉ abha.choudhary@utsouthwestern.edu)
The University of Texas Southwestern Medical Center

Soumya Adhikari
The University of Texas Southwestern Medical Center

Perrin White
The University of Texas Southwestern Medical Center

Research Article

**Keywords:** continuous glucose monitor, generalized linear model, hemoglobin A1c, Patient Health Questionnaire -9, telehealth

**Posted Date:** September 2nd, 2021

**DOI:** https://doi.org/10.21203/rs.3.rs-778544/v1

**License:** This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

**Version of Record:** A version of this preprint was published at BMC Pediatrics on March 10th, 2022. See the published version at https://doi.org/10.1186/s12887-022-03189-2.
Abstract

Background. The coronavirus disease-2019 (COVID-19) pandemic had widespread impacts on the lives of parents and children. We determined how the pandemic affected Type 1 diabetes patients at a large urban pediatric teaching hospital.

Methods. We compared patient characteristics, glycemic control, PHQ9 depression screen, in person and virtual outpatient encounters, hospitalizations and continuous glucose monitor (CGM) utilization in approximately 1600 patients in one-year periods preceding and following the local imposition of COVID-related restrictions on 3/15/2020 (“2019” and “2020” groups, respectively).

Results. In a generalized linear model, increasing age, non-commercial insurance, Black and Hispanic race/ethnicity, and non-utilization of CGMs were all associated with higher hemoglobin A1c (HbA1c), but there was no difference between the 2019 and 2020 groups. The time in range in CGM users was lower with non-commercial insurance and in Black and Hispanic patients; it improved slightly from 2019 to 2020. CGM utilization by patients with non-commercial insurance increased markedly. In 2020, patients with commercial insurance had fewer office visits, but insurance status did not influence utilization of the virtual visit platform. There was no change in hospitalization rates from 2019 to 2020 in either commercially or non-commercially insured patients, but patients with non-commercial insurance were hospitalized at markedly higher rates in both years. PHQ9 scores were unchanged.

Conclusions. Hospitalization rates, glycemic control and depression screening were unchanged in our large urban pediatric teaching hospital during the COVID pandemic. Increased utilization of CGM and rapid adoption of telemedicine may have ameliorated the impact of the pandemic on disease management.

Introduction

The coronavirus disease-2019 (COVID-19) pandemic disrupted daily life in many ways. In Texas, a state of emergency was declared on 3/13/2020 and a lockdown imposed on 3/21/2020. Non-essential businesses closed, schools were transitioned to virtual modes of education and most public activities ceased. The pandemic may have impacted care for many children with diabetes through lack of access to school nurses, altered care arrangements, loss of parental jobs and insurance, social isolation and psychological stress, and clinic closures.

We retrospectively examined the impact of the pandemic on outcomes including hospitalization, clinic visits, glycemic control and the frequency of depression in children and adolescents with Type 1 diabetes (T1D) in our institution.

Methods

Setting
The clinical setting and database were previously described (1). In brief, the study took place at Children's Medical Center Dallas, a large urban pediatric teaching hospital licensed for 487 beds, with a 72-bed satellite facility 22 mi (35 km) north. This study was approved by the UT Southwestern Institutional Review Board. Data were obtained using SAP (Walldorf, Germany) analytics to interrogate a Clarity database derived from our institutional Epic (Madison, WI) clinical data repository. Two sequential reports were created, a baseline “2019” pre-COVID group comprising encounters between 3/15/2019 and 3/14/2020 (the approximate day that COVID restrictions were imposed in Dallas County) and a “2020” post-COVID group representing encounters occurring between 3/15/2020 and 3/14/2021. Only patients with at least one outpatient encounter were included in either group.

**Coding and Statistical Analysis**

We excluded patients with type 2 diabetes, genetic diabetes, cystic fibrosis-related diabetes or secondary (induced by corticosteroids or other drugs) diabetes, and patients with duration of diabetes < 365 days at the time of their most recent encounter. Both inpatient admissions and observations, but not emergency department visits, with ICD10 codes of E10.10, E10.11, and E10.65 were counted as hospital admissions. Insurance status was coded as “commercial” (i.e., private-pay or provided by an employer) or “non-commercial,” (93% of such patients were in government programs, 7% uninsured or “other”). Race and ethnicity were recoded as a single variable with values of “White or Caucasian”, “Hispanic”, “Black or African American”, or “Other”; in our region, the vast majority of Hispanics are of Mexican origin. Number of office visits during the year was defined as the number of visits to our diabetes clinic with either a physician or a nurse practitioner, excluding education-only group classes. Virtual visits were defined similarly. Our clinic used an Alere Afinion Analyzer (Abbott Diagnostics, Lake Forest, IL) to measure hemoglobin A1c (HbA1c). We used the most recent HbA1c value in each year. Values > 15 (i.e., above the linear range of the assay) were recoded as 15. Patients were classified as CGM users if any CGM downloads were present in the database for the given year; the most recent two-week period available was used to assess time in range. Patients share their Dexcom CGM data with the clinic through the cloud-based Dexcom Clarity application. Freestyle Libre data were shared via Libreview. CGM metrics were documented in the electronic medical record at every visit. Time in range was defined as the proportion of CGM data points falling in the 70–180 range. Patient Health Questionnaire-9 (PHQ-9), a self-administered depression screening was offered to all patients with T1D 10 years and older who were seen in person. It was offered every 9 months or sooner if there were mental health concerns. A social worker was consulted if there was a failed screen. Statistical analysis was conducted in SAS 9.0. Differences in proportions were assessed by Fisher exact tests, and factors influencing continuous variables (HbA1c, CGM time in range, PHQ9 score) were identified using generalized linear models with age, gender, year, insurance status, race/ethnicity and (for HbA1c) CGM use as main effects.

**Results**

For all results, the “2020” group represents encounters occurring between 3/15/2020 (the approximate day that COVID restrictions were imposed in Dallas County) and 3/14/2021; the “2019” group comprises
encounters between 3/15/2019 and 3/14/2020. The demographic composition of the 2020 group is presented in Table 1.
**Table 1**
Outpatient visit frequency

| Visits | 0   | 1   | 2   | ≥ 3  | Total | p*     |
|--------|-----|-----|-----|------|-------|--------|
| Count of patients with each number of total outpatient visits, by year* |
| Commercial |
| 2019    | –   | 150 | 254 | 649  | 1053  |        |
| %       | –   | 14.2| 24.1| 61.6 | 100   |        |
| 2020    | –   | 252 | 331 | 401  | 984   |        |
| %       | –   | 25.6| 33.6| 40.8 | 100   |        |
| Total   | –   | 402 | 585 | 1050 | 2037  | < 0.0001 |
| Non-commercial |
| 2019    | –   | 139 | 172 | 382  | 693   |        |
| %       | –   | 20.0| 24.8| 55.1 | 100   |        |
| 2020    | –   | 150 | 179 | 318  | 647   |        |
| %       | –   | 23.2| 27.7| 49.1 | 100   |        |
| Total   | –   | 289 | 351 | 700  | 1340  | 0.09   |

Count of patients with each number of office and virtual visits in 2020

| Office | Commercial | 262 | 302 | 264 | 156 | 984 |
|--------|------------|-----|-----|-----|-----|-----|
| %      | 26.6       | 30.7| 26.8| 15.9| 100 |
| Non-commercial | 136 | 197 | 181 | 133 | 647 |
| %      | 21.0       | 30.4| 28.0| 20.6| 100 |
| Total  | 398        | 499 | 445 | 289 | 1631| 0.02 |

| Virtual | Commercial | 363 | 391 | 168 | 62  | 984 |
|---------|------------|-----|-----|-----|-----|-----|
| %       | 36.9       | 39.7| 16.5| 6.6 | 100 |

+ P values by Fisher Exact Tests

*Patients were included in the analysis for a given year only if they had at least one outpatient visit.
In response to the pandemic, all clinic visits were suspended on 3/16/2020 and a virtual visit platform was quickly put in place starting on 4/1/2020. Our operations gradually transitioned back to clinic visits starting on 5/1/2020 and gradually ramped up.

In 2020, the number of outpatient visits (including both clinic and virtual visits) per patient decreased markedly for those with commercial insurance but there was not a significant decrease per patient with non-commercial insurance (Table 2). Patients with commercial insurance had fewer office visits per patient than those with non-commercial insurance. However, there was no difference in utilization of the virtual visit platform in patients based on insurance status.

| Visits | 0 | 1 | 2 | ≥ 3 | Total | p+ |
|--------|---|---|---|-----|-------|----|
| Non-commercial | 240 | 251 | 107 | 49 | 647 |    |
| % | 37.1 | 38.8 | 16.5 | 7.6 | 100 |    |
| Total | 603 | 642 | 275 | 95 | 1631 | NS |

+ P values by Fisher Exact Tests

*Patients were included in the analysis for a given year only if they had at least one outpatient visit.
### Table 2
Count of patients with each number of admissions, by year

|                | Commercial |       |       | Total | P   |
|----------------|------------|-------|-------|-------|-----|
|                | Admission  | 0     | 1     | >2    |     |
| 2019           |            | 992   | 47    | 14    | 1053|
|                | %          | 94.2  | 4.5   | 1.3   | 100 |
| 2020           |            | 916   | 59    | 9     | 984 |
|                | %          | 93.1  | 6.0   | 0.9   | 100 |
| Total          |            | 1908  | 106   | 23    | 2037|
|                | %          |       |       |       | NS  |
| Non-Commercial |            | 581   | 82    | 30    | 693 |

|                |            |       |       |       |     |
| 2019           |            | 83.8  | 11.8  | 4.3   | 100 |
| 2020           |            | 543   | 75    | 29    | 647 |
|                |            | 83.9  | 11.6  | 4.5   | 100 |
| Total          |            | 1124  | 157   | 59    | 1340|

P values by Fisher Exact Tests.
P<0.0001 commercial vs non-commercial.

There was no change in hospitalization rates from 2019 to 2020 in either commercially or non-commercially insured patients (Table 3), but patients with non-commercial insurance were hospitalized at markedly higher rates (p < 0.0001) in both years.
Table 3
Factors influencing hemoglobin A1c, linear model

|               | Estimate | Standard Error | P     |
|---------------|----------|----------------|-------|
| Intercept     | 7.71     | 0.14           | <0.0001 |
| Age, y        | 0.05     | 0.01           | <0.0001 |
| Gender        |          |                |       |
| Male          | 0.00     |                |       |
| Female        | 0.11     | 0.06           | 0.06  |
| Year          |          |                |       |
| 2019          | 0.00     |                |       |
| 2020          | 0.04     | 0.06           | NS    |
| Insurance     |          |                |       |
| Commercial    | 0.00     |                |       |
| Non-commercial| 0.62     | 0.07           | <0.0001 |
| Race/ethnicity|          |                |       |
| White         | 0.00     |                |       |
| Black         | 1.31     | 0.09           | <0.0001 |
| Hispanic      | 0.41     | 0.08           | <0.0001 |
| Other         | -0.10    | 0.12           | NS    |
| CGM use       |          |                |       |
| Yes           | 0.00     |                |       |
| No            | 0.87     | 0.07           | <0.0001 |

Using data from October 2014 to October 2017, we had previously developed a predictive model for hospital admissions incorporating hospitalizations in the prior 12 months, HbA1c and non-commercial insurance as factors (1). To see if the model retained discrimination (i.e., predictive power) under the changed circumstances of the pandemic, we used data from the 2019 period to predict hospitalization in the 2020 period. As assessed by the area under the receiver operator characteristic curve (ROC AUC), discrimination actually improved from 0.746 in the original training dataset (1) to 0.761 in the present study. In the original training dataset, a risk score of 0.3 had 95% specificity and 29% sensitivity to predict hospitalization; in the present study, the same threshold had 94% specificity and 32% sensitivity. Thus, model performance was essentially unchanged during the pandemic.
The effects of the pandemic on glycemic control were examined in a generalized linear model (Table 4). Increasing age, non-commercial insurance, Black and Hispanic race/ethnicity, and non-utilization of continuous glucose monitors (CGM) were all associated with higher HbA1c, but there was no difference between the 2019 and 2020 groups. There was no change in CGM utilization in patients with commercial insurance (61.8% in 2019 and 61.4% in 2020), but CGM utilization by patients with non-commercial insurance increased markedly from 24.5% in 2019 to 35.7% in 2020 ($p = 0.001$), probably because Texas Medicaid began approving reimbursement for CGM in April 2020. CGM percent time in range was strongly correlated with HbA1c ($R^2 = 0.49$, $p < 0.0001$). Similar to the findings regarding HbA1c, time in range among patients utilizing CGM was lower in those with non-commercial insurance and in Black and Hispanic patients; it improved slightly from 2019 to 2020.

**Table 4**

Factors influencing CGM time in range (%), linear model

|              | Estimate | Standard Error | P    |
|--------------|----------|----------------|------|
| Intercept    | 45.59    | 2.02           | <0.0001 |
| Age, y       | -0.19    | 0.12           | NS   |
| Gender       |          |                |      |
| Male         | 0.00     |                |      |
| Female       | -0.03    | 0.92           | NS   |
| Year         |          |                |      |
| 2019         | 0.00     |                |      |
| 2020         | 1.93     | 0.92           | 0.04 |
| Insurance    |          |                |      |
| Commercial   | 0.00     |                |      |
| Non-commercial | -7.50   | 1.15           | <0.0001 |
| Race/ethnicity|         |                |      |
| White        | 0.00     |                |      |
| Black        | -7.60    | 1.49           | <0.0001 |
| Hispanic     | -2.96    | 1.40           | 0.03 |
| Other        | 1.74     | 1.83           | NS   |

We routinely screen for depression in our patients 10 years of age and older using the Patient Health Questionnaire-9 (PHQ9); the proportion of screened patients in the entire clinic population decreased in
2020 from 58.5–41.5% (p < 0.0001) because we did not attempt to have patients complete the questionnaire online. Among those screened, the only demographic factor associated with increased scores was female gender; there was no significant change from 2019 to 2020 (Table 5).

| Table 5  | Factors influencing PHQ9, linear model |
|----------|--------------------------------------|
|          | Estimate | Standard Error | P         |
| Intercept| 2.03     | 0.57           | 0.0003    |
| Age      | 0.00     | 0.03           | NS        |
| Year     |          |                |           |
| 2019     | 0.00     |                |           |
| 2020     | -0.20    | 0.17           | NS        |
| Insurance|          |                |           |
| Commercial|         |                |           |
| Non-commercial| 0.19 | 0.19           | NS        |
| Gender   |          |                |           |
| Male     | 0.00     |                |           |
| Female   | 0.74     | 0.17           | < 0.0001  |
| Race/ethnicity |       |                |           |
| White    | 0.00     |                |           |
| Black    | 0.20     | 0.24           | NS        |
| Hispanic | 0.13     | 0.22           | NS        |
| Other    | -0.20    | 0.36           | NS        |

**Discussion**

The COVID-19 pandemic has had a worldwide impact on glycemic control in diabetic patients. The International Society for Pediatric and Adolescent Diabetes (ISPAD) recommended maintaining good glycemic control as an effective strategy for preventing severe COVID-19 disease and death in this population. Higher HbA1c, minority race or ethnicity, and non-commercial insurance status are independently associated with increased rates of diabetic ketoacidosis in pediatric patients with T1D (1), indicating that these subgroups may be particularly vulnerable during the current pandemic. The
relatively high rates of COVID-19 in racial and ethnic minority communities may further increase their risk of poor outcomes (2). Insulin pumps and continuous glucose monitoring (CGM) use may improve glycemic control, but minority and economically disadvantaged populations have lower use of these devices (3), and unpublished observations). The pandemic has highlighted disparities in care for this population, who had already encountered barriers to access of care prior to the pandemic.

A review of 238 children in Alabama during the pandemic showed worsening glycemic control in children with Type 1 diabetes, with those on public insurance affected in greater proportion than those with private insurance (4). In both India (5) and Saudi Arabia (6), difficulties with obtaining insulin during the pandemic may have affected glycemic control. Conversely, use of advanced devices such as continuous glucose monitors and closed-loop insulin pumps during the pandemic was associated with stable or improved glycemic control in many locales including China (7), Italy (8-10), Greece (11) and Israel (12).

Adoption of telemedicine visits may improve outcomes in diabetic patients; retrospective data during the COVID-19 pandemic in 2727 Japanese diabetes patients showed both telemedicine and clinic visits improved glucose control (13). However, in a report of 28,977 patient visits over 2.5 years at a single US center, the odds of completing a visit via telemedicine were lower among non-English speaking and Medicaid insured pediatric patients. Socioeconomic status, affordability of internet services and cellular data, housing insecurity, loss of jobs, and unpredictable work schedules likely contributed to decreased uptake of telemedicine in this population (14).

In our large urban hospital setting, the COVID pandemic had no effect on glycemic control. CGM utilization increased in the non-commercial group during the pandemic due to improved coverage and efforts of our group to promote CGM access. Hospitalization rates were unchanged by the pandemic despite a decrease in office visits among patients with commercial insurance.

Rapid adoption of telemedicine, improved access to CGM and, perhaps, increased parental oversight of diabetes care likely helped maintain glycemic control and hospitalization rates at pre-pandemic levels (7).

**Strengths and Limitations**

The strengths of this study are the large sample size—over 1600 patients—and the inclusion of an ethnically and socioeconomically diverse population. On the other hand, our observations are limited to one center. We serve an urban population and our findings regarding adoption of telemedicine cannot be extrapolated to rural areas where there may have been issues with internet and cellular connectivity. Other than the PHQ-9, we have no before-and-after survey data on factors that might mediate pandemic-related changes in glycemic control such as quality of life, health habits, parental work history, physical activity or school attendance.

**Conclusions**
Hospitalization rates, glycemic control and incidence of depression were unchanged among children with type 1 diabetes in a large urban children's hospital during the first year of the COVID-19 pandemic. Increased adoption of continuous glucose monitors and extensive use of telemedicine visits may have ameliorated the impact of the pandemic on disease management.

Declarations

Ethics approval and consent to participate:

We did not need formal ethics approval. This complies with the national guidelines. This study was declared exempt by the Institutional Review Board of the University of Texas Southwestern Medical Center.

“STU-2021-0411: Your submission was reviewed and determined to meet Exempt criteria under 45 CFR 46.104(d). The Designated Reviewer made regulatory determinations for this study which may be found in eIRB in the Determinations tab”.

Consent for publication:

A waiver of informed consent from the IRB was obtained since this manuscript reported de-identified data and is a retrospective review.

Accordance:

We confirm that all methods were performed in accordance with the relevant guidelines.

Competing interests:

none

Availability of data material:

The datasets during and/or analyzed during the current study is available from the corresponding author on reasonable request.

Funding:

none
Author Contributions:

AC, SA, PCW designed the study; SA designed the database; PCW analyzed the data; AC and PCW wrote a first draft of the paper; AC, SA and PCW critically edited the manuscript.

Acknowledgements:

none

References

1. Mejia-Otero JD, Adhikari S, White PC. Risk factors for hospitalization in youth with type 1 diabetes: Development and validation of a multivariable prediction model. Pediatr Diabetes. 2020;21(7):1268–76.

2. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and Mortality among Black Patients and White Patients with Covid-19. N Engl J Med. 2020;382(26):2534–43.

3. Kahkoska AR, Shay CM, Crandell J, Dabelea D, Imperatore G, Lawrence JM, et al. Association of Race and Ethnicity With Glycemic Control and Hemoglobin A(1c) Levels in Youth With Type 1 Diabetes. JAMA Netw Open. 2018;1(5).

4. Gayoso M, Lim WY, Mulekar MS, Kaulfers A-MD. Effect of Covid-19 quarantine on diabetes Care in Children.

5. Verma A, Rajput R, Verma S, Balania VKB, Jangra B. Impact of lockdown in COVID 19 on glycemic control in patients with type 1 Diabetes Mellitus. Diabetes Metab Syndr. 2020;14(5):1213–6.

6. Al Agha AE, Alharbi RS, Almohammadi OA, Yousef SY, Sulimani AE, Alaama RA. Impact of COVID-19 lockdown on glycemic control in children and adolescents. Saudi Med J. 2021;42(1):44–8.

7. Wu X, Luo S, Zheng X, Ding Y, Wang S, Ling P, et al. Glycemic control in children and teenagers with type 1 diabetes around lockdown for COVID-19: A continuous glucose monitoring-based observational study. J Diabetes Investig. 2021.

8. Marigliano M, Maffeis C. Glycemic control of children and adolescents with type 1 diabetes improved after COVID-19 lockdown in Italy. Acta Diabetol. 2021;58(5):661–4.

9. Di Dalmazi G, Maltoni G, Bongiorno C, Tucci L, Di Natale V, Moscatiello S, et al. Comparison of the effects of lockdown due to COVID-19 on glucose patterns among children, adolescents, and adults with type 1 diabetes: CGM study. BMJ Open Diabetes Res Care. 2020;8(2).

10. Tornese G, Ceconi V, Monasta L, Carletti C, Faleschini E, Barbi E. Glycemic Control in Type 1 Diabetes Mellitus During COVID-19 Quarantine and the Role of In-Home Physical Activity. Diabetes Technol Ther. 2020;22(6):462–7.

11. Christoforidis A, Kavoura E, Nemtsa A, Pappa K, Dimitriadou M. Coronavirus lockdown effect on type 1 diabetes management on children wearing insulin pump equipped with continuous glucose
monitoring system. Diabetes Res Clin Pract. 2020;166:108307.

12. Brener A, Mazor-Aronovitch K, Rachmiel M, Levek N, Barash G, Pinhas-Hamiel O, et al. Lessons learned from the continuous glucose monitoring metrics in pediatric patients with type 1 diabetes under COVID-19 lockdown. Acta Diabetol. 2020;57(12):1511–7.

13. Onishi Y, Yoshida Y, Takao T, Tahara T, Kikuchi T, Kobori T, et al. Diabetes management by either telemedicine or clinic visit improved glycemic control during the coronavirus disease 2019 pandemic state of emergency in Japan. J Diabetes Investig. 2021.

14. Tilden DR, Datye KA, Moore DJ, French B, Jaser SS. The Rapid Transition to Telemedicine and Its Effect on Access to Care for Patients With Type 1 Diabetes During the COVID-19 Pandemic. Diabetes Care. 2021.

**Figures**

**Figure 1**

Utilization of virtual visits in relation to the COVID pandemic. Panel A shows COVID cases in the Dallas Forth-Worth area and Panel B shows diabetes clinic visits (virtual and in person) from 1/2020 to 3/2021.